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Abstract. Several recent findings suggest that targeting the endogenous cannabinoid system can be considered as a potential
therapeutic approach to treat Alzheimer’s disease (AD). The present study supports this hypothesis demonstrating that delta-9-
tetrahydrocannabinol (THC) or cannabidiol (CBD) botanical extracts, as well as the combination of both natural cannabinoids,
which are the components of an already approved cannabis-based medicine, preserved memory in APP/PS1 transgenic mice
when chronically administered during the early symptomatic stage. Moreover, THC + CBD reduced learning impairment in
APP/PS1 mice. A significant decrease in soluble A42 peptide levels and a change in plaques composition were also observed
in THC + CBD-treated APP/PS1 mice, suggesting a cannabinoid-induced reduction in the harmful effect of the most toxic
form of the A peptide. Among the mechanisms related with these positive cognitive effects, the anti-inflammatory properties
of cannabinoids may also play a relevant role. Here we observed reduced astrogliosis, microgliosis, and inflammatory-related
molecules in treated APP/PS1 mice, which were more marked after treatment with THC + CBD than with either THC or CBD.
Moreover, other cannabinoid-induced effects were uncovered by a genome-wide gene expression study. Thus, we have identified
the redox protein thioredoxin 2 and the signaling protein Wnt16 as significant substrates for the THC + CBD-induced effects
in our AD model. In summary, the present findings show that the combination of THC and CBD exhibits a better therapeutic
profile than each cannabis component alone and support the consideration of a cannabis-based medicine as potential therapy
against AD.
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INTRODUCTION 31
Alzheimer’s disease (AD) is the most common neu- 32
rodegenerative disease associated with dementia in the 33
elderly. While a small proportion of AD cases have a 34
genetic basis, the majority of cases are sporadic with 35
unknown etiology. A consistent feature of the AD 36
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brain is the presence of senile plaques composed of37
pathogenic extracellular deposits of amyloid- (A),38
a peptide derived from the aberrant processing of the39
trans-membrane amyloid- protein precursor (APP).40
A fragments are believed to play a central role41
in the genesis of the disease resulting in memory42
loss and behavioral changes. A second pathologi-43
cal hallmark of the disease is hyperphosphorylation44
of the microtubule-associated protein tau that forms45
intracellular neurofibrillary tangles. AD is also associ-46
ated with neuroinflammation and oxidative stress thus47
exacerbating neurodegenerative damage [1, 2]. The48
feeble effectiveness of current therapies against AD49
highlights the need for urgent development of new50
agents geared to preventing the disease or curbing its51
progression.52
Targeting the endocannabinoid system offers a53
multi-faceted approach to the treatment of AD as54
cannabinoid compounds provide neuroprotection by55
reducing neuronal damage, neuroinflammation, and56
oxidative stress, as well as by promoting intrinsic repair57
mechanisms [3–5]. Recent studies have demonstrated58
that chronic stimulation with selective synthetic ago-59
nists of CB1 and CB2 receptors, the most well-known60
cannabinoid receptors, reduce cognitive impairment61
and brain alterations associated with A produc-62
tion, in at least three different animal models of AD63
[6–9]. Promising results have also been obtained in a64
murine model of tauopathy using treatment with nat-65
ural cannabinoids [10]. Moreover, several in vitro and66
in vivo observations support the beneficial effects of67
CB1 and CB2 stimulation in AD models. Thus, the68
activation of CB1 receptor in vitro preserves neuron69
viability by reducing A-induced lysosomal mem-70
brane permeability [11] and suppressing pro-apoptotic71
signaling pathways [12]. CB2 receptor agonists induce72
A removal by human macrophages [13] and reduce73
microglial response to A [7, 14]. In addition, cer-74
tain cannabinoids are also capable of decreasing tau75
phosphorylation via CB1 or CB2 receptor activation [7,76
15, 16].77
The aim of the present study was to test78
the therapeutic properties of the combination of79
delta-9-tetrahydrocannabinol (THC) and cannabidiol80
(CBD), two phytocannabinoids produced by the plant81
Cannabis sativa that are known to modulate the82
endogenous cannabinoid system, in an animal model83
of AD. The compounds are the two main components84
of Sativex®, which is a cannabinoid-based medicine85
already launched in eleven countries (including the86
UK, Canada, Spain, Italy, and Germany), and approved87
in a further thirteen countries. Sativex® is a well-88
tolerated medicine prescribed for the treatment of 89
spasticity associated with multiple sclerosis and it 90
is also undergoing development for other therapeu- 91
tic applications including pain of various origins (i.e., 92
cancer) and Huntington’s disease [17, 18], a fact that 93
can facilitate the translation from basic research in AD 94
models to human cases. We have used APP/PS1 mice 95
as an animal model because they replicate the most 96
relevant features of AD, including cognitive impair- 97
ment and several pathological alterations such as A 98
deposition, dystrophic neurites, synaptic failure, mito- 99
chondrial dysfunction, and oxidative stress damage 100
[19, 20]. 101
MATERIALS AND METHODS 102
Animals 103
The experiments were carried out in male APP/PS1 104
mice and wild-type littermates aged 6 months (early 105
symptomatic phase) at the outset of the study. The gen- 106
eration of mice expressing the human mutated forms 107
APPswe and PS1dE9 has already been described 108
[19]. Animals were maintained under standard ani- 109
mal housing conditions in a 12-h dark-light cycle with 110
free access to food and water. Mice were randomly 111
assigned to treatment groups and the experiments 112
were conducted under blind experimental conditions. 113
All animal procedures were carried out following 114
the guidelines of the European Communities Coun- 115
cil Directive 2010/63/EU and with the approval of the 116
local ethical committees of the University of Barcelona 117
and University Pompeu Fabra. 118
Pharmacological treatment 119
THC enriched botanical extract (containing 120
67.1% THC, 0.3% CBD, 0.9% cannabigerol, 0.9% 121
cannabichromene, and 1.9% other phytocannabinoids) 122
and CBD enriched botanical extract (containing 123
64.8% CBD, 2.3% THC, 1.1% cannabigerol, 3.0% 124
cannabichromene, and 1.5% other phytocannabinoids) 125
were supplied by GW Pharmaceuticals Ltd (Cam- 126
bridge, UK). The extracts (THC, 0.75 mg/kg; CBD, 127
0.75 mg/kg; THC + CBD, 0.75 mg/kg each) were 128
dissolved in 5% ethanol, 5% Tween, and 90% saline, 129
and these mixtures were injected intra-peritoneally 130
(i.p.) in a volume of 10 mL/kg body weight. The 131
human equivalent dose (HED) calculated with the 132
formula for dose translation based on body surface 133
area [20] corresponds to 0.04 mg/kg for each cannabi- 134
noid, what is equivalent to the administration of 135
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a single Sativex® oromucosal spray (2.8 mg THC136
+2.8 mg CBD) in a human being weighting 70 kg,137
and is lacking of psychoactivity. Animals were138
treated once a day for 5 weeks with the extracts139
or the corresponding vehicle (wild-type, n = 7–11;140
APP/PS1, n = 7–8 per group). After 10 days of141
washing period, animals were subjected to behavioral142
evaluation.143
Behavioral evaluation of cognitive performance144
and sample collection145
Two-object recognition test: This paradigm was146
performed in a V-maze (Panlab, Barcelona, Spain)147
because it improves the exploration time of the ani-148
mals with respect to a classical open field. On day149
1, mice were habituated for 9 min, allowing them to150
freely explore the apparatus. On the second day, mice151
were placed for 9 min in the maze, where two identi-152
cal objects were situated at the end of the arms, and153
the time that the mice spent exploring each object was154
recorded. Then, 24 h after the training session, animals155
were placed again in the V-maze where one of the156
two familiar objects was replaced by a novel object.157
The time that the animals spent exploring the two158
objects was recorded and an object recognition index159
(RI) was calculated as the difference between the time160
spent exploring the novel (TN) and the familiar object161
(TF), divided by the total time spent exploring the two162
objects [RI = (TN-TF)/(TN + TF)]. Animals exhibiting163
memory impairments revealed a lower object recogni-164
tion index.165
Active avoidance test: After the two-object recogni-166
tion test, the animals were allowed to rest for 4 days167
before starting the active avoidance test. Then, the mice168
were trained to avoid an aversive stimulus associated169
with the presentation of a conditioned stimulus (CS) in170
a two-way shuttle box apparatus (Panlab, Barcelona,171
Spain). The CS was a light (10 W) switched on in172
the compartment in which the mouse was placed. The173
CS was received 5 s before the onset of the uncondi-174
tioned stimulus (US) and overlapped it for 25 s. At the175
end of the 30-s period, both CS and US were auto-176
matically turned off. The US was an electric shock177
(0.2 mA) continuously applied to the grid of the floor.178
A conditioned response was recorded when the animal179
avoided the US by changing from the compartment180
where it received the CS to the opposite compartment181
within the 5-s period after the onset of the CS. If ani-182
mals failed to avoid the shock, they could escape it by183
crossing during the US (25 s), and this was recorded184
as unconditioned response. Between each trial session,185
there was an inter-trial interval of 30 s. Animals were 186
subjected to five daily 100-trial active avoidance ses- 187
sions. Each day, the mice were placed in the shuttle 188
box for 10 min before the start of each session to allow 189
them to explore the box. Data are expressed as the 190
total number of conditioned changes, converted to the 191
area under the curve (AUC) using a standard trapezoid 192
method. 193
At the end of the behavioral testing, the animals 194
were sacrificed by cervical dislocation and their brains 195
rapidly removed from the skull and processed for study. 196
One hemisphere was dissected on ice, immediately 197
frozen, and stored at −80◦C until used for the pro- 198
tein quantification and the gene expression study. The 199
other hemisphere was fixed in 4% paraformaldehyde 200
and processed for immunohistochemistry. 201
Aβ immunohistoc emistry 202
Fixed tissue samples were embedded in paraffin, and 203
coronal sections, 4m thick, were cut with a micro- 204
tome. Consecutive de-waxed sections were incubated 205
with 98% formic acid (3 min) and then treated with 206
citrate buffer (20 min) to enhance antigenicity. Then 207
endogenous peroxidases were blocked by incubation 208
in 10% methanol-1% H2O2 solution (15 min). Sections 209
were blocked with 3% normal horse serum solution 210
and then incubated at 4◦C overnight with the primary 211
antibody against A40 (1 : 100, Merck Millipore, Bil- 212
lerica, MA, USA) or A42 (1 : 50, Merck Millipore). 213
Sections were subsequently rinsed and incubated with 214
biotinylated secondary antibody (Dako), followed by 215
EnVision + system peroxidase (Dako), and finally with 216
chromogen diaminobenzidine and H2O2. Sections 217
were lightly counterstained with hematoxylin. After 218
staining, the sections were dehydrated and cover- 219
slipped for observation under a Nikon Eclipse E800 220
microscope (Nikon Imaging Inc., Tokyo, Japan; Objec- 221
tive: 10x). The cortical total A42 and A40 burden 222
was calculated as the percentage of the area of amy- 223
loid deposition in plaques with respect to the total 224
area in 9 representative pictures taken from the cere- 225
bral cortex of each animal, corresponding to the main 226
regions where A42 and A40 deposition is observed 227
in APP/PS1 mice. The ratio between A42 and A40 228
deposition in each plaque was calculated by com- 229
paring the specific staining with each antibody in at 230
least 10 plaques per animal in consecutive sections. 231
A quantification was calculated using the Adobe® 232
Photoshop® CS4 software (Adobe Systems Inc., San 233
Jose, CA, USA), as previously described [20]. All the 234
APP/PS1 treated animals were analyzed.
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Aβ soluble quantiﬁcation: Enzyme-linked235
immunosorbent assay (ELISA)236
Fresh-frozen mouse brain cortex was homoge-237
nized in 4 volumes (wt:vol) of TBS extraction238
buffer (140 mM NaCl, 3 mM KCl, 25 mM Tris (pH239
7.4), 5 mM EDTA, and protease inhibitor cocktail240
(Roche Molecular Systems, Pleasanton, CA, USA).241
Homogenate was spun 100,000 g × 1 h, and the super-242
natant was saved as the soluble fraction for A243
quantification. A40 and A42 Human ELISA kits244
(InvitrogenTM Corporation, Camarillo, CA, USA)245
were used to quantify the levels of A40 and A42 pep-246
tides in the brain soluble fractions. Quantitative deter-247
mination was carried out according to the manufac-248
turer’s instructions, as previously described [21]. A40249
and A42 levels were normalized to the total amount250
of protein from each individual sample (BCA method,251
Thermo Fisher Scientific, Wilmington, DE, USA). Six252
APP/PS1 mice per treatment were analyzed.253
Double-labeling immunoﬂuorescence254
De-waxed sections were incubated with 98% formic255
acid (3 min) for A immunofluorescence and then256
treated with citrate buffer (20 min) to enhance anti-257
genicity. Sections were stained with a saturated258
solution of Sudan black B for 30 min (Merck Milli-259
pore) to block lipofuscin autofluorescence, then rinsed260
in 70% ethanol and washed in distilled water. After a261
blockade with 10% fetal bovine serum (90 min), the262
sections were incubated at 4◦C overnight with combi-263
nations of primary antibodies against A (clone 6F/3D264
1 : 50, Dako), glial fibrillary acidic protein (GFAP;265
1 : 250, Dako) or IBA1 (1 : 250, Wako, Richmond, VA,266
USA). After washing, the sections were incubated with267
Alexa488 or Alexa546 fluorescence secondary anti-268
bodies against the corresponding host species (1 : 400,269
Molecular Probes, Eugene, OR, USA). Then they270
were washed and mounted in Immuno-Fluore Mount-271
ing medium (ICN Biomedicals, Solon, OH, USA),272
sealed, dried overnight, and examined with a Nikon273
Eclipse E800 microscope. The specific GFAP and274
IBA1 immunostaining density was calculated in refer-275
ence to the A plaque area in 5 representative pictures276
taken from the cortex of each animal using the Adobe®277
Photoshop® CS4 software. Six animals per each group278
were used for quantifications.279
RNA microarray studies280
RNA from frozen cortex samples of treated mice281
was extracted following the instructions of the sup-282
plier (Rneasy Mini Kit, Qiagen® GmbH, Hilden, 283
Germany). RNA quality control was tested with the 284
Agilent Bioanalyzer (Agilent Technologies Inc, Santa 285
Clara, CA, USA), and the RNA concentration was 286
evaluated using a NanoDrop™ Spectrophotometer 287
(Thermo Fisher Scientific). A total of 24 samples (6 288
APP/PS1 samples per treatment) were analyzed by 289
microarray hybridization with the GeneChip® Mouse 290
Gene 1.0 ST Array from Affimetrix (Santa Clara, 291
CA, USA). Bioinformatic analysis was performed with 292
a three (+1) step on the probe values to turn them 293
into comparable gene-level expression values: back- 294
ground correction (RMA), normalization (Quantiles), 295
summarization (Median Polish), and transcript-level 296
summarization (Average). Non-specific filtering was 297
applied to rule out controls, low signal genes, and low 298
variability genes. This pre-processing left 5,606 genes 299
for further study. Functional annotation and biological 300
term enrichment analysis were carried out using the 301
DAVID database (http://david.abcc.ncifcrf.gov/). We 302
used p < 0.05 as the cut-off point to determine whether 303
Kyoto Encyclopedia of Genes and Genomes (KEGG) 304
pathways were significantly enriched. Each group was 305
composed by 6 samples. 306
Quantitative PCR 307
1g total RNA was reverse-transcribed with cDNA 308
synthesized with the High-Capacity cDNA Reverse 309
Transcription kit (Applied Biosystems). Quantifica- 310
tion of the mRNA levels was performed in duplicate 311
reactions with gene-specific TaqMan® probes and 312
the TaqMan® Universal PCR Master Mix (Applied 313
Biosystems). House-keeping genes used were Aars, 314
Hprt, and Xpnpep1 [22]. QPCR was performed using 315
the Applied Biosystems 7900HT Fast Real-Time PCR 316
System. Samples were analyzed with the double delta 317
CT (CT) method using vehicle-treated APP/PS1 318
samples as control. Six animals per group were 319
analyzed. 320
Gel electrophoresis and western blotting 321
Samples of the cerebral cortex were homogenized 322
in RIPA lysis buffer (50 mM Tris/HCl buffer, pH 7.4 323
containing 2 mM EDTA, 0.2% Nonidet P-40, 1 mM 324
PMSF, protease, and phosphatase inhibitor cocktails, 325
Roche Molecular Systems, USA). The homogenates 326
were centrifuged for 15 min at 13,000 rpm. Pro- 327
tein concentration was determined with the BCA 328
method (Thermo Scientific). Equal amounts of protein 329
(20g) for each sample were loaded and separated 330
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by electrophoresis on sodium dodecyl sulfate poly-331
acrylamide gel electrophoresis (SDS-PAGE) (10%)332
gels and transferred onto nitrocellulose membranes333
(Amersham, Freiburg, Germany). Non-specific bind-334
ings were blocked by incubation in 3% albumin in PBS335
containing 0.2% Tween for 1 h at room temperature.336
After washing, membranes were incubated overnight337
at 4◦C with the antibodies against extracellular signal-338
regulated kinase (ERK)1/2 phospho Thr202/Tyr204339
Thr185/Tyr187 (1 : 1,000, Millipore), ERK1/2 (1 : 200,340
Santa Cruz Biotechnology, Dallas, TX, USA), thiore-341
doxin 2 (Txn2, 1 : 1,000, Proteintech, Chicago, IL,342
USA) and wingless-related integration site 16 (Wnt16,343
1 : 5,000, GeneTex, Irvine, CA, USA). Protein load-344
ing was monitored using an antibody against -tubulin345
(1 : 10,000, Abcam). Membranes were then incubated346
for 1 h in the appropriate HRP- conjugated secondary347
antibodies (1 : 2,000, Dako), and immunocomplexes348
were revealed by chemiluminescence reagent (ECL,349
Amersham). Densitometric quantification was carried350
out with TotalLab v2.01 software (Pharmacia, Swe-351
den). Bands were normalized to -tubulin. Six animals352
per group were analyzed.353
Statistical analysis354
The sample size for experimentation was com-355
puted using the Power and Precision software (Biostat,356
Englewood, NJ, USA), assuming a power of 95% and357
no missing data. Statistical analysis was performed358
with the SPSS® Statistics v21.0 software (IBM, New359
York, NY, USA). The normality of the data was360
assessed with the Shapiro-Wilk test and as a conse-361
quence parametric statistical tests were used for the362
analysis of all the data in the study. Data were analyzed363
with two-way ANOVA with genotype and treatment364
as between factors (memory, AUC, western blotting365
quantifications) or one-way ANOVA with treatment as366
between factor (A, glia, and gene expression quantifi-367
cations), followed by Tukey’s post hoc when required.368
Learning data (conditioned changes) were analyzed by369
two-way ANOVA with day of training as within factor370
and genotype as between factor. In all the experiments,371
the significance level was set at p < 0.05.372
RESULTS373
Natural cannabinoids reduce cognitive deﬁcits in374
AβPP/PS1 mice375
Daily administration of THC (0.75 mg/kg, i.p.),376
CBD (0.75 mg/kg, i.p.) botanical extracts, or the com-377
bination of THC and CBD (0.75 mg/kg each botanical 378
extract, i.p.) during 5 weeks at the early stages of 379
the symptomatic phase (6 months) blunted the mem- 380
ory impairment observed in vehicle-treated APP/PS1 381
mice when compared to wild-type animals on the 382
two-object recognition test (Fig. 1A). Thus, two- 383
way ANOVA revealed a significant treatment effect 384
(F(3,55) = 3.57, p < 0.05) and interaction between gen- 385
type and treatment (F(3,55) = 12.92, p < 0.001), but 386
not genotype effect. Subsequent Tukey’s post hoc 387
tests revealed that THC (p < 0.001), CBD (p < 0.01), 388
and THC + CBD (p < 0.05) significantly increased the 389
recognition index of APP/PS1 mice when com- 390
pared to vehicle-treated littermates. Chronic exposure 391
to THC botanical extract resulted in reduced mem- 392
ory performance in wild-type mice when compared 393
to vehicle-treated littermates (p < 0.05). However, 394
this deleterious effect was not seen in CBD- and 395
THC + CBD-treated wild mice as no impaired memory 396
performance was observed in these animals. No signif- 397
icant difference in the total exploration time during the 398
memory acquisition session or the memory test was 399
observed between groups (Supplementary Table 1), 400
discarding any possible impact of the treatments on the 401
anxiety levels or the activity of mice. Animals exhib- 402
ited no preference for any object during the acquisition 403
session. 404
The learning performance of mice was evalu- 405
ated in the active avoidance test by recording the 406
number of conditioned changes during 5 consecu- 407
tive training days. The AUC revealed a significant 408
reduction in the learning performance of vehicle- 409
(p < 0.01) and CBD-treated (p < 0.05) but not in THC- 410
or THC + CBD-treated APP/PS1 mice when com- 411
pared to wild littermates (Fig. 1B). When compared 412
day by day, the number of conditioned changes 413
achieved by mice was reduced in vehicle-treated 414
APP/PS1 mice on day 3 (p < 0.05), day 4 (p < 0.01), 415
and day 5 (p < 0.001; Fig. 1 C), in THC-treated on 416
day 5 (Fig. 1D) and in CBD-treated mice on day 417
3 (p < 0.05), day 4 (p < 0.01) and day 5 (p < 0.01; 418
Fig. 1E) when compared with wild-type animals. In 419
contrast, APP/PS1 mice chronically treated with the 420
combination of THC + CBD did not evidence such 421
learning impairment at any day (Fig. 1F). No signif- 422
icant treatment effect was observed respect vehicle 423
group neither in wild-type nor APP/PS1 mice. These 424
results demonstrate that the THC + CBD combination 425
rescued APP/PS1 learning impairment in the active 426
avoidance paradigm when administered at the begin- 427
ning of the symptomatic stage. See Supplementary 428
Table 2 for statistical details. 429
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Fig. 1. A) Memory performance of animals treated during the early symptomatic stage (6 months). APP/PS1 mice chronically treated with
vehicle exhibit a significant reduction in the recognition index when compared to corresponding wild-type littermates. However, chronic THC
(0.75 mg/kg, i.p.), CBD (0.75 mg/kg, i.p.) botanical extracts, and THC + CBD (0.75 mg/kg each, i.p.) administration induce memory improvement
in APP/PS1 when compared to wild-type animals. Interestingly, chronic THC induces a significant reduction in the memory performance of
wild-type animals. B-F) The number of conditioned changes in the active avoidance test was recorded during 5 consecutive days in order to
evaluate the learning performance of mice. B) Statistical analysis from the Area Under the Curve (AUC) reveals a global reduction in the
learning performance of vehicle- and CBD-treated but not in THC- or THC + CBD-treated APP/PS1 mice when compared to wild littermates.
The comparison of the conditioned changes achieved by mice every training day reveals a significant reduction in APP/PS1 mice treated with
vehicle from day 3 to day 5 (C), in THC-treated on day 5 (D), and in CBD-treated mice from day 3 to day 5 (E) when compared with wild-type
animals. In contrast, APP/PS1 mice chronically treated with the combination of THC + CBD do not evidence such learning impairment at any
day, thus demonstrating a positive effect (F). No significant treatment effect is observed respect vehicle group either in wild-type (light gray
dashed line) or APP/PS1 mice (dark gray dashed line). Data are expressed as the mean values ± SEM. p < 0.05, p < 0.01, p < 0.001
genotype effect; p < 0.05, p < 0.01, p < 0.001 compared to vehicle. §p < 0.05 compared to THC group.
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The combination of THC and CBD alters Aβ430
processing in AβPP/PS1 mice431
Chronic treatment with THC, CBD, or the combi-432
nation of both did not significantly modify the total433
A burden (F(3,28) = 0.73, N.S.; Fig. 2B) or the A42434
(F(3,22) = 0.62, N.S.) and A40 burden (F(3,22) = 0.30,435
N.S.; Fig. 2C) in the cortex of APP/PS1 mice,436
although there was a tendency to reduced A depo-437
sition in THC + CBD-treated animals. Similarly, no438
significant treatment effect was observed in the total439
A burden in the hippocampus of APP/PS1 mice440
(F(3,17) = 0.83, N.S.; Fig. 2B), which is much lower441
than the A burden observed in the APP/PS1 mice442
cortex, as expected. However, a significant reduc-443
tion in A42 (F(3,22) = 7.88, p < 0.001), but not A40444
(F(3,22) = 1.62, N.S), protein levels was observed in445
the cortical soluble fraction of THC + CBD-treated446
APP/PS1 mice when compared to vehicle- (p < 0.01),447
THC- (p < 0.01), and CBD-treated mice (p < 0.05), thus448
demonstrating a protective effect of the combination449
of both cannabinoids in APP/PS1 animals by reduc-450
ing the most toxic form of the A peptide (Fig. 2D).451
The THC + CBD treatment also induced a change452
(F(3,23) = 3.169, p < 0.05) in the composition of A453
plaques since the ratio A42/A40 in each plaque was454
increased in treated APP/PS1 mice when compared455
to control group (p < 0.05) (Fig. 2E, F), suggesting a456
facilitation of A42 deposition that could be related457
to the reduction of the most toxic A42 soluble con-458
tents. None of the A forms studied was detectable in459
wild-type animals, as expected (data not shown).460
Natural cannabinoids reduce Aβ461
deposition-related astrogliosis and cytokine462
expression in AβPP/PS1 mice463
One-way ANOVA revealed a treatment effect464
in the astrogliosis (F(3,20) = 10.86, p < 0.001) and465
microgliosis (F(3,20) = 2.53, p < 0.05) associated to A466
deposition in APP/PS1 mice. A significant reduc-467
tion in the number of astrocytes around A plaques468
was observed in mice treated with THC (p < 0.01),469
CBD (p < 0.001), or the combination of the two470
compounds (p < 0.05) when compared with vehicle-471
treated APP/PS1 mice, as revealed with quantitative472
double-labeling immunofluorescence (Fig. 3A, B).473
However, the number of microglial cells associated474
with A plaques was only significantly reduced by the475
THC + CBD combination (p < 0.05) when compared476
to vehicle-treated APP/PS1 animals (Fig. 3A, C).477
No significant effect on the number of astrocytes and478
microglial cells was observed in the cortex of treated 479
wild-type mice (data not shown). To assess possible 480
inflammatory changes associated with cannabinoid 481
compounds, we evaluated the expression levels of a 482
panel of cytokine-related genes, which have been pre- 483
viously demonstrated to underlie the inflammatory 484
response in APP/PS1 mice and AD brains (Lo´pez- 485
Gonza´lez et al., in preparation), by quantitative PCR. 486
As shown in Table 1, the combination of THC + CBD 487
resulted in a marked modification of the neuroin- 488
flammatory responses, which was greater than that 489
resulting from treatment with THC or CBD alone. 490
Reduced inflammatory responses involved a colony 491
stimulating factor receptor (Csf3r), a complement sys- 492
tem component (C1qtnf7), a cell surface adhesion 493
protein (Itgb2), Fc receptors (Fcgr1, Fcgr2b), a pro- 494
inflammatory cytokine (Il6st), a regulator of myeloid 495
cell cycle (Inpp5d), and toll-like receptors (Tlr4, 496
Tlr7). The THC + CBD combination also reduced the 497
expression of two genes related to anti-inflammatory 498
cytokines (Il10rb, Tgfb1). 499
Natural cannabinoids modify brain gene 500
expression in AβPP/PS1 mice 501
Additional transcription modifications associated 502
with cannabinoid effects in APP/PS1 mice were 503
assessed with RNA microarrays. Natural cannabi- 504
noids induced a differential gene expression profile 505
in APP/PS1 mice as revealed the heatmap obtained 506
from microarrays studies (Fig. 4A). The number of 507
genes significantly modulated in relation to vehicle- 508
treated APP/PS1 mice was 142 upregulated and 142 509
down-regulated in THC-treated mice; 125 upregu- 510
lated and 166 down-regulated in CBD-treated mice; 511
and 187 upregulated and 136 down-regulated in the 512
THC + CBD group (p < 0.05). The Venn’s diagram 513
shows that only 23 genes were commonly regu- 514
lated by the three treatments (Fig. 4B). The KEGG 515
enrichment analysis of the results allowed to dis- 516
cover functional-related gene groups significantly 517
modulated by treatments and pointed to degradation 518
processes, immunomodulation, mitochondrial func- 519
tion, and mitogen-activated protein kinase 3 (Mapk3) 520
and wingless-type MMTV integration site family, 521
member 16 (Wnt16) signaling pathways, among oth- 522
ers, as relevant molecular mechanisms underlying the 523
effects of natural cannabinoids in APP/PS1 trans- 524
genic mice (Supplementary Table 3). Eight candidate 525
genes were chosen for validation on the basis of 526
their potential functional relevance and their high- 527
fold change in treated APP/PS1 mice. The statistical 528
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A B
C D
E F
Fig. 2. A) Scheme showing the cortical brain areas (dashed squares) analyzed for A burden quantification in each animal. Neither total A
burden (B) nor A42 or A40 burden (C) are significantly modified in APP/PS1 mice cortex by chronic treatment with THC, CBD, or the
combination of the two, in spite of the tendency toward decrease in THC + CBD-treated animals. D) Soluble A40 and A42 levels in cortical
homogenates from APP/PS1 mice chronically treated with THC, CBD, and THC + CBD during the early symptomatic phase. The THC + CBD
combination significantly reduces protein levels of soluble A42 when compared to vehicle-treated controls, revealing the protective effect of
the combination of the natural cannabinoids. E) Reduction in the A42 soluble contents can be related, in part, to a change in the composition of
plaques since THC + CBD-treated APP/PS1 mice present increased A42 respect A40 deposition in each plaque when compared to vehicle-
treated animals. F) Representative images of the A42 (right) and A40 (left) specific immunoreactivity in consecutive cortical sections of
APP/PS1 mice treated during the early symptomatic phase. Scale bar represents 100m. Counts are expressed as the mean values ± SEM.
p < 0.05, p < 0.01 compared to vehicle. §p < 0.05 compared to THC group. &p < 0.05 compared to CBD group.
Un
co
rre
cte
d A
uth
or
 P
ro
of
E. Aso et al. / Cannabinoids Reduce AD-Like Phenotype in Mice 9
Fig. 3. A) Representative images of double GFAP (red, upper panels) or IBA1 (red, lower panels) and A (green) immunoreactivity in cortical
sections of APP/PS1 mice chronically treated during the early symptomatic phase with natural cannabinoids. Scale bar represents 25m.
B) Quantification of the GFAP staining around the A plaques reveals a significant reduction of the astroglial response in APP/PS1 mice
chronically treated with THC, CBD, or the combination of the two. C) Quantification of the IBA1 staining around the A plaques reveals a
significant reduction in microglial response only in APP/PS1 mice chronically treated with the combination of THC + CBD. Data are expressed
as the mean values ± SEM. p < 0.05, p < 0.01 p < 0.001 compared to vehicle.
analysis of the quantitative PCR resulted in: adeny-529
late cyclase 3 (Adcy3; F(3,20) = 1.54, N.S.), cytochrome530
c oxidase subunit VIIc (Cox7c; F(3,20) = 2.30, N.S.),531
Mapk3 (F(3,20) = 5.76, p < 0.01), nitric oxide synthase532
1 (Nos1; F(3,20) = 3.76, p < 0.05), proteasome subunit,533
beta type, 2 (Psmb2; F(3,20) = 3.37, p < 0.05), thiore-534
doxin 2 (Txn2;F(3,20) = 5.08,p < 0.01), ubiquitin (Ubb;535
F(3,20) = 3.182, p < 0.05), and Wnt16 (F(3,20) = 2.22,536
p < 0.05). Thus, a Mapk3, Psmb2, Txn2, and Wnt16537
decrease was validated in THC + CBD-treated mice538
(Fig. 4C). Decrease expression of Nos1 and Ubb539
was observed by quantitative PCR in THC + CBD,540
which was in contrast with the increase found in RNA541
microarray. Finally, Adcy3 and Cox7c modifications542
seen in microarrays were not validated with PCR.
Natural cannabinoids modulate MAPK3, Txn2, 543
and Wnt16 protein levels in AβPP/PS1 mice 544
We assessed the correlation between the 545
cannabinoid-induced alteration of Mapk3, Txn2, 546
and Wnt16 gene expression and the levels of the 547
proteins coded by those genes using western blotting. 548
In spite of decreased Mapk3 mRNA, no modifica- 549
tions in the expression of ERK1 (Genotype effect: 550
F(1,31) = 3.13, N.S.; Treatment effect: F(3,31) = 2.15, 551
N.S.; Interaction: F(3,31) = 1.26, N.S.) were seen in 552
treated APP/PS1 mice (Fig. 5A). However, natural 553
cannabinoids induced a significant modulation of 554
ERK1, but not ERK2, phosphorylation (Geno- 555
type effect: F(1,31) = 0.93, N.S.; Treatment effect: 556
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Table 1
mRNA expression levels of several cytokine-related genes involved in the inflammatory response in APP/PS1 mice
Cytokine-related genes APP/PS1
Vehicle THC CBD THC + CBD
Anti-inflammatory cytokines Il10ra 1.02 ± 0.09 0.90 ± 0.05 0.92 ± 0.07 0.88 ± 0.06
Il10rb 1.01 ± 0.07 1.08 ± 0.04 0.96 ± 0.08 0.78 ± 0.03∗.§
Tgfb1 1.03 ± 0.12 0.86 ± 0.05 0.84 ± 0.08 0.71 ± 0.07∗
Cell Surface Adhesion Itgb2 1.01 ± 0.07 0.95 ± 0.05 1.04 ± 0.15 0.75 ± 0.08∗
Chemokines Ccl3 1.04 ± 0.12 1.21 ± 0.14 1.19 ± 0.10 0.82 ± 0.16
Ccl4 1.03 ± 0.10 1.16 ± 0.10 1.39 ± 0.10∗ 0.97 ± 0.17
Ccl6 1.04 ± 0.12 1.24 ± 0.09 1.19 ± 0.12 0.99 ± 0.09
CxCl10 1.22 ± 0.35 1.21 ± 0.21 1.04 ± 0.19 0.95 ± 0.18
Complement system C1ql1 1.01 ± 0.05 1.15 ± 0.05 1.04 ± 0.03 1.11 ± 0.13
C1qtnf7 1.08 ± 0.19 0.95 ± 0.08 0.99 ± 0.03 0.75 ± 0.08&
C3ar1 1.00 ± 0.04 0.99 ± 0.04 1.03 ± 0.07 0.91 ± 0.06
C4b 1.02 ± 0.09 0.89 ± 0.03 1.07 ± 0.12 0.87 ± 0.12
Colony stimulating factor receptors Csf1r 1.01 ± 0.05 1.01 ± 0.03 0.96 ± 0.05 0.90 ± 0.05
Csf3r 1.02 ± 0.08 1.02 ± 0.10 0.86 ± 0.05 0.71 ± 0.07∗,§
Fc receptors Fcgr1 1.02 ± 0.09 1.08 ± 0.06 1.00 ± 0.06 0.85 ± 0.08§
Fcgr2b 1.01 ± 0.07 1.11 ± 0.07 1.08 ± 0.09 0.87 ± 0.05§
Pro-inflammatory cytokines Il6st 1.01 ± 0.06 0.95 ± 0.07 0.98 ± 0.07 0.77 ± 0.07∗
Tnfrsf1a 1.02 ± 0.08 1.15 ± 0.08 1.15 ± 0.05 1.12 ± 0.09
Regulator of myeloid cells Inpp5d 1.01 ± 0.05 0.92 ± 0.08 0.82 ± 0.10 0.60 ± 0.09∗,§
Toll-like receptors Tlr4 1.02 ± 0.09 0.90 ± 0.11 0.80 ± 0.08 0.68 ± 0.05∗
Tlr7 1.06 ± 0.15 1.01 ± 0.11 0.96 ± 0.16 0.63 ± 0.06∗,§
Values are calculated with the Ct method, using the mean of three housekeeping genes (Aars, Hprt, Xpnpep1) and vehicle-treated APP/PS1
as references. ∗p < 0.05 versus Vehicle; §p < 0.05 versus THC, &p < 0.05 versus CBD.
F(3,31) = 5.18, p < 0.01; Interaction: F(3,31) = 3.73,557
p < 0.05). Thus, CBD increased the levels of phospho-558
ERK1 in wild-type animals when compared to the559
vehicle (p < 0.05) or THC + CBD (p < 0.01) groups.560
In contrast, THC and THC + CBD induced a ten-561
dency to reduce the phosphorylation of ERK1 in562
APP/PS1 mice, which was apparently enhanced in563
vehicle-treated transgenic animals (Fig. 5A). Those564
results indicate that cannabinoid compounds could565
differentially regulate ERK1 signaling.566
Natural cannabinoids modulated the levels of Txn2567
in treated mice (Genotype effect: F(1,31) = 0.71, N.S.;568
Treatment effect: F(3,31) = 5.56, p < 0.01; Interaction:569
F(3,31) = 9.22, p < 0.001). APP/PS1 mice exhibited570
decreased Txn2 protein levels after treatment with571
vehicle (p < 0.05) and THC (p < 0.05), which was572
also apparent but not significant after CBD exposure,573
when compared to wild-type littermates (Fig. 5B).574
This deficiency in Txn2 levels could account to575
impaired capability to cope with oxidative components576
in APP/PS1 mice. Interestingly, the combination of577
THC + CBD induced a strong increase in the Txn2 pro-578
tein levels (p < 0.01 with respect to vehicle or CBD;579
p < 0.001 with respect to THC), which completely580
reversed this Txn2 deficiency observed in APP/PS1581
mice (Fig. 5B).582
Regarding the signaling protein Wnt16, a significant 583
effect of treatment was also observed (Genotype effect: 584
F(1,31) = 2.59, N.S.; Treatment effect: F(3,31) = 5.64, 585
p < 0.01; Interaction: F(3,31) = 1.67, N.S.). Both THC 586
and the combination of THC + CBD increased the 587
levels in APP/PS1 mice when compared to vehicle- 588
treated animals (p < 0.05). THC-treated APP/PS1 589
mice exhibited significantly higher Wnt16 protein lev- 590
els than corresponding wild-type controls (p < 0.01) 591
(Fig. 5C). 592
DISCUSSION 593
According to the protective hypothesis of cannabi- 594
noid compounds in neurodegenerative diseases, the 595
present findings show that treatment with natural 596
cannabinoids at non-psychoactive doses reduces cog- 597
nitive impairment and several pathological processes 598
occurring in APP/PS1, a model of AD, when chron- 599
ically administered at the early symptomatic phase. 600
Thus, THC and CBD, as well as the combina- 601
tion of both natural cannabinoids, reduces memory 602
impairment exhibited by APP/PS1 mice in the two- 603
object recognition test, but only the combination of 604
THC + CBD was able to prevent learning deficiency 605
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Fig. 4. A) Heat map generated from RNA microarray data reflecting the differential gene expression profile induced by cannabinoid compounds.
Blue: decreased expression. Red: increased expression. Headings: Vehicle (yellow), THC (blue), CBD (green), THC + CBD (red). B) Venn’s
diagram showing the number of genes significantly regulated by natural cannabinoids. C) Real-time PCR validated the results obtained with
microarray techniques in at least 4 out of 8 candidate genes, confirming decreased expression of Mapk3, Psmb2, Txn2, and Wnt16 genes in
THC + CBD-treated APP/PS1 mice. Data are expressed as the mean values ± SEM. p < 0.05 compared to vehicle. &p < 0.05, &&p < 0.01
compared to CBD.
of transgenic mice in the active avoidance test, con-606
sidered a complex cognitive task. As THC and CBD607
are supposed to produce their effects by acting on608
different signaling pathways [23], the present results609
with combined THC and CBD can be interpreted610
as a summative effect or as an interaction of the611
two compounds resulting in the potentiation of each612
cannabinoid, as previously suggested [24, 25]. The613
present findings are in agreement with a recent report614
conducted in parallel demonstrating positive behav-615
ioral effects of THC + CBD in a murine model of616
tauopathy [10]. Importantly, the cannabinoid doses 617
employed in this study are devoid of psychoactivity 618
[26] and their HED corresponds to a single Sativex® 619
administration, what means that the potential transla- 620
tion of our results to human beings might result in a 621
safe and well-tolerated approach taking into consider- 622
ation that multiple sclerosis patients receiving up to 12 623
Sativex® administrations per day reported a relatively 624
low side-effect profile [27]. 625
A collateral observation deserves attention. In con- 626
trast to APP/PS1 mice, memory impairment occurs 627
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Fig. 5. Western blot quantification of proteins codified by genes differentially expressed in treated mice: ERK1 (Mapk3), thioredoxin 2 (Txn2),
and wingless-related integration site (Wnt16). A) No significant change in the total amount of ERK1 is observed in any treatment group, in spite
of the tendency toward increased total ERK1 in THC + CBD-treated APP/PS1 mice. CBD significantly increases the levels of phosphorylated
ERK1 in wild-type animals. In contrast, THC and THC + CBD slightly decrease ERK1 phosphorylation without statistical significance. B)
THC + CBD completely reverses the Txn2 deficiency exhibited by vehicle- and THC-treated APP/PS1 mice. C) THC and THC + CBD increase
the levels of Wnt16 protein in cortical homogenates of APP/PS1 treated mice. In the upper part of each panel are representative immunoblots for
ERK1/2, Txn2, and Wnt16, and corresponding tubulin loading control. Densitometric quantifications are expressed as the mean values ± SEM.
p < 0.05, p < 0.01 genotype effect. p < 0.05, p < 0.01, compared to vehicle. §§§p < 0.001 compared to THC. &&p < 0.01 compared to
CBD.
in wild-type mice chronically exposed to the THC-628
enriched extract at doses that are known not to produce629
acute amnesia-like effects in mice [26]. This obser-630
vation warns about the chronic effects of THC in631
healthy individuals and is in accordance with sev-632
eral human studies revealing that long-term use of633
cannabis can be associated with disruption of short- 634
term memory, working memory, and attention skills 635
[28, 29]. It is known that certain cannabinoids, such 636
as THC, affect cognitive function modulating sig- 637
naling pathways critically implicated in learning and 638
memory [30]. The molecular reorganization of endoge- 639
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nous cannabinoid system in AD [31] and the altered640
neuronal signaling occurring during the neurodegen-641
erative processes may account for the discrepancy642
between the effects of THC in wild-type and AD-like643
transgenic mice. However, wild-type mice chroni-644
cally receiving THC + CBD do not exhibit memory645
impairment. This observation supports previous work646
showing that CBD is able to antagonize THC-induced647
deficits in memory tasks [32], and highlights the rele-648
vance of combining the two natural cannabinoids, THC649
and CBD, to mitigate the negative consequences of650
THC administration.651
A remarkable finding of this study is the altered652
A processing induced by the THC + CBD combi-653
nation in APP/PS1 mice. Even though THC, CBD,654
and the combination of both did not significantly mod-655
ify cortical or hippocampal A burden in APP/PS1656
mice in spite of a tendency to decrease in the ani-657
mals treated with THC + CBD, the combination of658
both compounds reduced soluble A42, but not A40659
protein levels, thus showing a protective effect by660
reducing the quantity of the most toxic soluble A form661
in APP/PS1 animals [33]. We have also observed662
a change in amyloid plaques composition since an663
increase in the A42/A40 ratio in each plaque was664
observed in THC + CBD-treated APP/PS1 mice, sug-665
gesting a cannabinoid-induced facilitation of the A42666
deposition that could account at least in part for the667
specific reduction of soluble A42 observed and likely668
to decrease its toxicity. The recently described A42669
clearance facilitation across the blood-brain barrier by670
cannabinoids [8, 34], might also contribute to the THC-671
CBD-induced reduction of the A toxicity in our AD672
model.673
AD progression involves aberrant glial activation674
and neuroinflammation that contribute to neuronal dys-675
function, which in turn drives a vicious cycle of further676
glial activation and neuronal damage [35]. Several677
studies have shown anti-inflammatory effects of nat-678
ural and synthetic CB1 or CB2 agonists, as well as679
CBD, in multiple in vitro and in vivo AD models [6–8,680
14, 36–38]. The present observations confirm previous681
findings by demonstrating a reduction of the astroglio-682
sis associated with A deposition in APP/PS1 mice683
treated with THC, CBD, or the combination of both. In684
addition, THC + CBD significantly reduced microglio-685
sis and the expression of several cytokines and related686
molecules in APP/PS1 mice. Most importantly, the687
combination of THC + CBD resulted more effective688
than either THC or CBD alone.689
The ubiquitous distribution of endocannabinoid sys-690
tem and its polyvalent functionality suggest that the691
positive cognitive effects observed in APP/PS1 after 692
chronic treatment with natural cannabinoids might be 693
due to multiple mechanisms run in parallel, beyond 694
to the already known anti-inflammatory properties or 695
the role in reducing A toxicity. A useful tool to iden- 696
tify novel mechanisms that may contribute to a certain 697
effect is the microarrays technology. This technique 698
involves large-scale monitoring of relative differ- 699
ences in RNA abundance between samples. Thus, we 700
identified additional mechanisms contributing to the 701
natural cannabinoid effects in APP/PS1 mice by RNA 702
microarrays. The functional analysis of the results 703
pointed to molecular degradation, immunomodulation, 704
mitochondrial function, and Mapk3 and Wnt16 sig- 705
naling pathways, among others, as relevant pathways 706
targeted by cannabinoids. First, we focused on validat- 707
ing the cannabinoid effects on the Mapk3 signaling. 708
Previous in vitro studies have shown that the stimu- 709
lation of endogenous cannabinoid system decreases 710
ERK1/2 pro-inflammatory signaling in response to 711
A, resulting in reduced toxicity [12, 39]. Although 712
the total amount of ERK1, the protein coded by 713
Mapk3, is not significantly modulated by cannabi- 714
noids in the present model, THC and THC + CBD 715
decrease ERK1 phosphorylation. We also observed an 716
increase in ERK1/2 phosphorylation in wild-type ani- 717
mals receiving CBD, which is contrast to a previous 718
study showing reduced phospho-ERK1/2 in the cor- 719
tex of rats chronically exposed to CBD [40]. These 720
discrepancies could be due to different experimen- 721
tal conditions. Together, these observations point to 722
the need for further studies geared to elucidating the 723
ERK response in wild and APP/PS1 mice treated with 724
cannabinoids. 725
Another important contribution of the present study 726
is the induction of Txn2 protein levels by the 727
THC + CBD combination, in contrast to the reduced 728
Txn2 mRNA expression observed in the microarray 729
study as well as by quantitative PCR. The diver- 730
gence between the mRNA and protein levels could 731
account for compensatory mechanisms directed to 732
regulate Txn2 functionality. THC + CBD completely 733
reversed Txn2 deficiency in APP/PS1 mice, which 734
also occurs in AD patients [41]. This nuclear gene 735
encodes a mitochondrial member of the thioredoxin 736
family, a group of small multifunctional redox-active 737
proteins [42]. The encoded protein is a key compo- 738
nent of the mitochondrial antioxidant system which 739
is responsible for the clearance of reactive intermedi- 740
ates and repairs proteins with oxidative damage and 741
may play important roles in the regulation of the mito- 742
chondrial membrane potential and in protection against 743
Un
co
rre
cte
d A
uth
or
 P
ro
of
14 E. Aso et al. / Cannabinoids Reduce AD-Like Phenotype in Mice
oxidant-induced apoptosis [43, 44]. Therefore, it can744
be assumed that increased Txn2 levels provide protec-745
tion against oxidative damage in our model.746
Finally, little is known about the role of Wnt16747
signaling in cells and to our knowledge there is no748
specific information about Wnt16 function in brain.749
The Wnt gene family consists of structurally related750
genes which encode secreted signaling proteins. These751
proteins have been implicated in oncogenesis and in752
several developmental processes, including regulation753
of cell fate and patterning during embryogenesis, as754
well as in axon guidance during development and in755
response to traumatic injury in adult central nervous756
system [45]. Moreover, activation of the Wnt signaling757
pathway prevents A-induced neurotoxicity in vitro,758
probably through the modulation of the GSK3/-759
catenin pathway [46]. Wnt16 gene is a member of the760
Wnt gene family. It contains two transcript variants761
diverging at the 5’ termini. These two variants are pro-762
posed to be the products of separate promoters and not763
to be splice variants from a single promoter. They are764
differentially expressed in normal tissues, one of which765
(variant 2) is expressed at significant levels only in the766
pancreas, whereas another one (variant 1) is expressed767
more ubiquitously with highest levels in adult kidney,768
placenta, brain, heart, and spleen [47]. Thus, it is tempt-769
ing to speculate that increased cannabinoid-induced770
Wnt16 expression may reduce A neurotoxicity and771
contribute to maintain axon integrity in vivo. Never-772
theless, additional experiments are required to validate773
this hypothesis.774
In summary, here we provide evidence of the ther-775
apeutic effects of the THC + CBD combination, over776
THC or CBD alone, by acting at different levels mod-777
ifying A metabolism, reducing soluble A42 levels,778
astrogliosis, microglia, and several molecules of neu-779
roinflammation. Speculatively, it is c nceivable that780
the effects of THC + CBD combination are also due781
to the increase protein expression of thioredoxin 2782
and Wnt16. Nevertheless, additional experiments are783
required to validate this hypothesis. This is accompa-784
nied by a reduction of memory deficits and increased785
learning capacity in APP/PS1 transgenic mice used786
as a model of AD. The present findings give insights787
for a further clinical trial to test the effectiveness of788
THC + CBD in AD patients.789
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